Delving into the Latest Updates on Carotuximab with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Carotuximab (USAN/INN), Chimeric anti-CD105 antibody, Chimeric Antibody TRC-105

+ [6]

Target

ENG

Action

inhibitors

Mechanism

ENG inhibitors(endoglin inhibitors), Angiogenesis inhibitors

Therapeutic Areas

NeoplasmsUrogenital DiseasesSkin and Musculoskeletal Diseases+ [1]

Active Indication

Metastatic castration-resistant prostate cancerHormone receptor positive HER2 negative breast cancerLocally advanced breast cancer+ [3]

Inactive Indication

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBladder Cancer+ [22]

Originator Organization

Roswell Park Comprehensive Cancer Center

TRACON Pharmaceuticals, Inc.

Active Organization

TRACON Pharmaceuticals, Inc.

Novartis Pharmaceuticals Corp.

Kairos Pharma Ltd.

+ [1]

Inactive Organization

Ambrx, Inc.

Santen Pharmaceutical Co., Ltd.

License Organization

Kairos Pharma Ltd.

Santen Pharmaceutical Co., Ltd.

TRACON Pharmaceuticals, Inc.

+ [2]

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Sequence Code 319922187H

Source: *****

Sequence Code 319922188L

Source: *****

This is an open-label, multi-site study of apalutamide with carotuximab in patients who have progressed on androgen receptor signaling inhibitor (ARSI) therapy. This study will begin with a safety assessment in the first 10 subjects (part 1: Safety Lead-in). If the combination is deemed safe, the trial will proceed to the Phase II stage. The purpose of this study is to compare progression free survival (PFS) between patients receiving apalutamide and apalutamide + carotuximab using Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and Prostate Cancer Working Group 3. The secondary objectives are to describe adverse events related to the intervention, overall response rate (ORR), proportion of patients resistant to apalutamide that benefit from the addition of carotuximab, and to determine the ORR, radiographic PFS, and biochemical PFS in the overall population.

Start Date27 Dec 2023

Sponsor / Collaborator

Cedars-Sinai Medical Center

NCT05401110

/ RecruitingPhase 1IIT

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) Version 5, to find the maximum tolerated dose. The secondary objectives include evaluating the rate of objective response rate, duration of response, progression-free survival, and disease control rate, along with assessing biomarkers through tumor tissue and circulating tumor DNA.

Start Date15 Sep 2023

Sponsor / Collaborator

Cedars-Sinai Medical Center

NCT02520063

/ Active, not recruitingPhase 1/2IIT

A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer

This study will test how well a new combination of three drugs (Letrozole, Everolimus, and TRC105) is tolerated and how well it works in Stage 2 and 3 breast cancer when given prior to definitive surgery. Letrozole blocks the estrogen receptor expressed by many breast cancers while everolimus blocks signals that drive cancer cells to grow. TRC105 is an investigational drug that blocks the formation and growth of blood vessels that feed the cancer and promote its growth. The goal of this study is to investigate the safety and efficacy of this multitargeted approach in breast cancer.

Start Date23 Feb 2019

Sponsor / Collaborator

The University of Alabama at Birmingham

[+2]

100 Clinical Results associated with Carotuximab

Login to view more data

100 Translational Medicine associated with Carotuximab

Login to view more data

100 Patents (Medical) associated with Carotuximab

Login to view more data

75

Literatures (Medical) associated with Carotuximab

01 Jul 2025·DRUG RESISTANCE UPDATES

CD105 blockade restores osimertinib sensitivity in drug-resistant EGFR-mutant non-small cell lung cancer

Article

Author: Sankar, Kamya ; Li, Xiamo ; Thiruvalluvan, Manish ; Araña, Manuel ; Gayhart, Matthew ; Billet, Sandrine ; Villamejor, Anton L ; Waissengrin, Barliz ; You, Sungyong ; Reckamp, Karen L ; Bhowmick, Neil A ; Lopategui, Jean ; Lownik, Joseph ; Milshteyn, Larry ; Liu, Zhenqiu ; Posadas, Edwin M ; Kim, Hyoyoung

AIM:

To investigate the role of CD105 in mediating drug resistance to EGFR-targeted therapy in non-small cell lung cancer (NSCLC).

METHODS:

Imaging mass cytometry was conducted on 66 NSCLC tumors, 44 of which had EGFR mutations. We correlated clinical variables, including overall survival, with CD105 (endoglin) expression, a co-receptor for bone morphogenetic protein (BMP) signaling. Two osimertinib-resistant EGFR-mutant cell lines were developed to study the effects of EGFR and CD105 disruption. Single cell RNA sequencing of the isogenic parental and osimertinib resistant lines was performed. Additionally, ATAC sequencing and Single Cell ENergetIc metabolism by profiling Translation inHibition analysis (SCENITH) was used to assess promoter chromatin status and glycolytic state.

RESULTS:

We found a negative correlation between CD105 expression and overall survival in patients. Treatment with osimertinib or EGFR knockdown significantly elevated CD105 expression in EGFR-mutant cell lines. Single-cell RNA sequencing identified a subset of cells with heightened endothelial characteristics and altered pyrimidine metabolism, associated with osimertinib resistance. These cells exhibited a slow-cycling behavior, characterized by elevated chromatin condensation and reduced glycolysis. Combining osimertinib with carotuximab, a CD105 neutralizing antibody, significantly reduced the slow-cycling transcriptomic signature, increased chromatin accessibility, and restored glycolysis compared to osimertinib treatment alone. Mass spectrometry confirmed that carotuximab re-engaged EGFR signaling by coupling it with CD105. Consequently, carotuximab re-sensitized resistant tumors to osimertinib by increasing their mitotic index and ERK signaling in mouse models.

CONCLUSION:

Carotuximab effectively reduced the slow-cycling cell population and restored osimertinib sensitivity, offering a promising strategy for managing refractory NSCLC.

01 Mar 2025·LIFE SCIENCES

Anti-Endoglin monoclonal antibody prevents the progression of liver sinusoidal endothelial inflammation and fibrosis in MASH

Article

Author: Igreja Sa, Ivone Cristina ; Havelek, Radim ; Fikrova, Petra ; Tripska, Katarina ; Eissazadeh, Samira ; König, Matthias ; Nemeckova, Ivana ; Mohammadi, SeyedehNiloufar ; Micuda, Stanislav ; Vasinova, Martina ; Rathouska, Jana Urbankova ; Theuer, Charles ; Nachtigal, Petr

Liver sinusoidal endothelial inflammation/dysfunction and fibrosis are a crucial part of Metabolic Dysfunction Associated Steatohepatitis (MASH) development. TRC105 and M1043 are anti-endoglin (ENG) monoclonal antibodies that bind ENG. In this study, we hypothesized that treatment with anti-ENG antibodies would prevent the progression of LSECs inflammation and fibrosis in vivo and in vitro. MASH was induced in male C57BL/6 mice fed a choline-deficient L-amino acid-defined high-fat diet (CDAA-HFD) for 4 or 8 weeks. In the rescue study, mice were divided into three groups: a control group (chow diet), a MASH group (CDAA-HFD + IgG), and a rescue group (CDAA-HFD + M1043). Later, two groups received rat IgG1 (10 mg/kg) and M1043 (10 mg/kg). In in vitro experiments, inflammation was induced in human LSECs by ox-LDL (50 μg/mL) and treated with TRC105 (300 μg/mL). Liver sinusoidal endothelial inflammation/dysfunction in MASH animals was characterized by endothelial overexpression of ENG, VCAM-1, and ICAM-1 and reduced VE-cadherin and p-eNOS/eNOS expression. M1043 treatment prevented the overexpression of ENG, VCAM-1, and ICAM-1, the progression of liver fibrosis, and the increase of liver-to-body weight ratio. In vitro experiments with TRC105 confirmed the prevention of LSECs inflammation development by reduced ENG and VCAM-1 expression, as well as decreased THP-1 monocytic cell adhesion in ox-LDL activated LSECs. In conclusion, we demonstrate that anti-ENG antibody treatment can prevent LSECs inflammation and fibrosis progression in a MASH animal model and LSECs inflammation in vitro. Thus, we propose directly targeted ENG may represent a promising pharmacological approach for addressing LSECs inflammation and liver fibrosis.

01 Apr 2023·Breast cancer research and treatment

A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer

Article

Author: Acosta, Edward P ; Vaklavas, Christos ; Wei, Shi ; Stringer-Reasor, Erica M ; Grizzle, William E ; Forero-Torres, Andres ; Li, Yufeng ; Elkhanany, Ahmed M ; Ryan, Kevin J ; Theuer, Charles P ; Yang, Eddy S

Abstract:

Purpose:

In nonmetastatic hormone receptor-positive and Her2-negative breast cancer, preoperative endocrine therapies can yield outcomes similar with chemotherapy. We evaluated the tolerability and preliminary antitumor activity of preoperative letrozole, everolimus, and carotuximab, a monoclonal antibody targeting endoglin, in nonmetastatic breast cancer.

Methods:

Eligible patients had newly diagnosed, stage 2 or 3, hormone receptor-positive and Her2/neu-negative breast cancer. Patients received escalating doses of everolimus; the dose of letrozole and carotuximab were fixed at 2.5 mg PO daily and 15 mg/kg intravenously every 2 weeks, respectively. The primary objective was to determine the safety and tolerability of the combination. Secondary objectives included pharmacokinetic and pharmacodynamic studies and assessments of antitumor activity.

Results:

Fifteen patients enrolled. The recommended phase 2 dose of everolimus in combination with letrozole and carotuximab was 10 mg PO daily. The most frequent adverse events were headache (67%), fatigue (47%), facial flushing and swelling (47%), gingival hemorrhage (40%), epistaxis (33%), nausea and vomiting (27%). Headache constituted a dose-limiting toxicity. At least two signs of mucocutaneous telangiectasia developed in 92% of patients. Carotuximab accumulated in the extravascular space and accelerated the biodistribution and clearance of everolimus. All patients had residual disease. Gene expression analyses were consistent with downregulation of genes involved in proliferation and DNA repair. Among 6 patients with luminal B breast cancer, 5 converted to luminal A after one cycle of therapy.

Conclusion:

Letrozole, everolimus, and carotuximab were tolerated in combination at their single-agent doses. Pharmacokinetic studies revealed an interaction between everolimus and carotuximab.

Trial registration:

This trial is registered with ClinicalTrials.gov (Identifier: NCT02520063), first posted on August 11, 2015, and is active, not recruiting.

27

News (Medical) associated with Carotuximab

16 Jul 2025

·pipelinereview.com

Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer

LOS ANGELES, CA, USA I July 15 2025 I Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 clinical trial of ENV-105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The interim safety analysis of the trial demonstrated that ENV-105, a first-in-class CD105 antagonist, was well tolerated when combined with standard of care hormone therapy, apalutamide, from the first ten enrolled patients. Thus far, there have been no dose-limiting toxicities or unexpected adverse events reported to date. In addition, the treatment-related side effects were manageable with standard supportive care. Notably, no Grade 3 or 4 toxicities were observed. “The favorable safety profile observed in this Phase 2 study is encouraging, as it validates our belief in ENV-105’s clinical potential and supports continued development in a patient population with limited effective treatment options,” said John Yu, MD, Kairos Pharma CEO. With one million men in the U.S. being diagnosed with prostate cancer annually, and millions more worldwide, the development of resistance to current hormone therapies is a growing unmet need with an increasingly aging population. Castration-resistant prostate cancer refers to tumors that grow despite receiving hormone blocking agents. Treatment options remain limited after hormone therapies fail. Kairos Pharma seeks to provide a safe and effective alternative for these patients with ENV-105. The randomized Phase 2 trial aims to enroll 100 patients in total, and is presently accruing patients at Cedars-Sinai Medical Center, City of Hope, and Huntsman Cancer Center. The study is designed to evaluate the safety, tolerability, and early signs of efficacy of ENV-105, a CD105 antagonist, in men whose disease has progressed following standard hormone-based therapies. Interim efficacy data from the trial are expected to be reported in September 2025. Kairos Pharma plans to engage with regulatory agencies to discuss the design of a potential pivotal Phase 3 study, based on emerging data. For more information about the study, visit https://clinicaltrials.gov/search?cond=Prostate%20Cancer&intr=Carotuximab . Kairos Pharma is a biopharmaceutical company advancing a pipeline of targeted therapies for cancer patients with high unmet medical needs. Our mission is to bring safe, effective, and science-driven solutions that improve the efficacy of existing standard of care to the most challenging forms of cancer. SOURCE: Kairos Pharma

Phase 2Clinical Result

04 Jun 2025

·pipelinereview.com

Kairos Pharma Ltd. Announces New Data on Small Molecule GITR Ligand Agonist KROS 101 as Promising Cancer Immunotherapy at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

LOS ANGELES, CA, USA I June 03, 2025 I Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces its presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting highlighting data on its investigational small molecule GITR ligand agonist KROS101. ASCO is being held May 30-June 3, 2025 at McCormick Place in Chicago, Ill. In the presentation titled, “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,” the study authors presented their findings that demonstrated KROS 101’s capability to act as a potent glucocorticosteroid-induced tumor necrosis factor receptor (GITR) ligand agonist with dual mechanisms of action. The study authors also indicated their study showed KROS 101 enhanced T cell function by promoting proliferation and increasing cytotoxicity, enhancing the immune response by boosting cytokine production and tumor cancer cell killing. In addition, the study found that KROS101 reduced T reg-mediated suppression by reducing T reg populations, which reverses immune system suppression and enhances effector T cell activity. Further, the study showed KROS to be superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg decrease, enhancing tumor cell cytotoxicity and preventing T cell exhaustion. TRX518 was previously in clinical trials. The presentation can be accessed here . John Yu, M.D., Kairos CEO commented, “These results strongly support continued study of KROS101 as a cancer immunotherapy, as they show strong activity in boosting the immune system while targeting and killing tumor cells. Its dual mechanism of action provides significant opportunity to a market that remains in desperate need of new solutions. We continue to believe that KROS 101 has the potential to help optimize cancer treatment and we look forward to discussing these findings with the medical and scientific communities while providing additional progress updates as appropriate.” About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. ( NYSE American: KAPA ) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, with the trials aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com . SOURCE: Kairos Pharma

ImmunotherapyASCOPhase 2Phase 1

28 Apr 2025

·www.businesswire.com

Kairos Pharma, Ltd. Announces Data to be Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, announces it will be presenting at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting to be held May 30-June 3, 2025 at McCormick Place, Chicago, Ill. The poster is titled, “Effect of KROS 101, a small molecule GITR ligand agonist, on T effector cells, T reg cells and intratumoral CD8 T cell cytotoxicity,” and will be presented on June 2. John Yu, M.D., Kairos CEO commented, “We look forward to the opportunity to continue to share data regarding our platform assets at one of the most prestigious oncology meetings in the world. We believe that KROS 101 has the potential to help optimize cancer treatment and we look forward to discussing our findings with the medical and scientific communities.” About Kairos Pharma, Ltd. Based in Los Angeles, California, Kairos Pharma, Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105 – a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer, with the trials aimed at addressing significant unmet medical needs. For more information, visit kairospharma.com. CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s Annual Report on Form 10-K and our other filings made with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.

Phase 2ASCOPhase 1

100 Deals associated with Carotuximab

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D11260	Carotuximab	-	DB06322

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hemangiosarcoma	Phase 3	United States	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	Austria	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	France	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	Germany	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	Italy	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	Poland	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	Spain	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hemangiosarcoma	Phase 3	United Kingdom	TRACON Pharmaceuticals, Inc.	13 Feb 2017
Hormone receptor positive HER2 negative breast cancer	Phase 2	United States	Novartis Pharmaceuticals Corp.	23 Feb 2019
Hormone receptor positive HER2 negative breast cancer	Phase 2	United States	TRACON Pharmaceuticals, Inc.	23 Feb 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02520063 (CTgov)	Phase 1/2	Locally advanced breast cancer \| Hormone receptor positive HER2 negative breast cancer	15	Letrozole+Everolimus+TRC105 (Phase I Cohort 2)	xysrzvsccy = ngcibkyksh asqtrmxyvx (sikdihrosm, xisdmpnbmm - kvosdsseag) View more	-	21 Aug 2023
				Letrozole+Everolimus+TRC105 (Phase I Cohort 1)	xysrzvsccy = lzejxvnqwd asqtrmxyvx (sikdihrosm, nfedmjxvec - qfozdzdbml) View more
NCT02979899 (TAPPAS, Pubmed) Manual	Phase 3	Hemangiosarcoma	114	TRC105+Pazopanib	runukpxcly(wiyliccafs) = tmfcfozfso hrwphkrovk (sthifjkdlj, 2.8 - 8.3)	Positive	31 Mar 2022
				Pazopanib	runukpxcly(wiyliccafs) = hocnnhjgqq hrwphkrovk (sthifjkdlj, 2.9 - NR)
NCT03211234 (CTgov)	Phase 2	Wet age-related macular degeneration	76	Lucentis (Sham)	akzwszahqo(vgigxsugqd) = gbthqdbpko hvusptthtj (zjqswwbfhz, 8.937) View more	-	13 Jul 2021
				DE-122+Lucentis (2.0 mg DE-122)	akzwszahqo(vgigxsugqd) = himegzlfdh hvusptthtj (zjqswwbfhz, 11.485) View more
NCT03418324 (CTgov)	Phase 2	Prostatic Cancer \| Metastatic castration-resistant prostate cancer	11	Abiraterone+TRC105 (Arm A: TRC105 + Abiraterone)	owneubfpfx = pzxuakrwzt qidthhbqmp (cicejjlocz, cfbbutesnh - anfdjoswjl) View more	-	30 Dec 2020
				Enzalutamide+TRC105 (Arm E: TRC105 + Enzalutamide)	owneubfpfx = egiveocnis qidthhbqmp (cicejjlocz, cdfabyrfld - hcvxcejoyb) View more
NCT01806064 (TRAXAR, CTgov)	Phase 1/2	Metastatic Renal Cell Carcinoma	173	Axitinib+TRC105 (P1b: 8 mg/kg TRC105 Wkly + 5 mg Axitinib BID)	qowtftjxao = gwzcvgjofz yjadhbntsc (nrxyhqjhhp, qyfukyblco - rvvhbppkmq) View more	-	19 Oct 2020
				Axitinib+TRC105 (P1b: 10 mg/kg TRC105 Wkly + 5 mg Axitinib BID)	qowtftjxao = wfgqbwscjk yjadhbntsc (nrxyhqjhhp, lqasxwtrup - zffwrewlcz) View more
NCT02560779 (CTgov)	Phase 1/2	Hepatocellular Carcinoma \| Unresectable Hepatocellular Carcinoma	27	Carotuximab+Sorafenib (Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib)	btjxizulon = ofxypykqvz qeyhcsllif (nqlnyuuqcj, nvtpregmhy - wasmabslrz) View more	-	17 Jul 2020
				Carotuximab+Sorafenib (Carotuximab (10 mg/kg Weekly) Plus Sorafenib)	btjxizulon = hvvcqtrpwk qeyhcsllif (nqlnyuuqcj, zplkftuaci - qbuqloqlyo) View more
NCT03181308 (CTgov)	Phase 1	metastatic non-small cell lung cancer	11	Nivolumab+TRC105 (8 mg/kg TRC105 + Nivolumab)	xwezlubaya = gbjipqxuma mhlqzcmuqd (drpncgtkey, tahcjocnvd - ilfktdeeou) View more	-	24 Jun 2020
				Nivolumab+TRC105 (10 mg/kg TRC105 + Nivolumab)	xwezlubaya = nltdfgqjly mhlqzcmuqd (drpncgtkey, mzshaxkvnu - dnbiptxrsx) View more
NCT02979899 (TAPPAS, CTgov)	Phase 3	Hemangiosarcoma	128	Votrient	ijpvmspnin(ivdshncdbl) = wmcnuznxsn pbftfjtrht (rphfdblehm, pkjrhdznwq - izfxevwspv) View more	-	12 May 2020
NCT01975519 (CTgov)	Phase 1/2	Sarcoma \| Locally Advanced Soft Tissue Sarcoma \| Metastatic Soft Tissue Sarcoma ... View more	111	TRC105+Pazopanib (TRC105 Plus Pazopanib)	totuurmcsp = xloebnngyx ucijbgbftl (fofjjancwy, xyiyplasjr - aiotclukwi) View more	-	12 May 2020
				TRC105+Pazopanib (8 mg/kg TRC105 + Pazopanib)	qxlzktvspi(brbsgquqgk) = nroonkypqo tthpmzaxnr (diozqxyrvx, pfvpsgsfod - hpaglsbbpy) View more
NCT02555306 (PAVE, CTgov)	Phase 1/2	Wet age-related macular degeneration	12	DE-122 (0.5 mg of DE-122)	dcvldmpsrd(yqzzijocgj) = wvwhixjiij drljcosipm (qoywhacbqa, 2.1) View more	-	14 Jan 2020
				DE-122 (1.0 mg of DE-122)	dcvldmpsrd(yqzzijocgj) = weqsjqtjur drljcosipm (qoywhacbqa, 5.0) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Carotuximab

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation